3.4 Massive Hemoptysis, Complex Pleural Effusions & Thoracic Drainage

ABIM Critical Care Medicine Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Orientation: Format, Blueprint & Study Strategy

1.1 ABIM Critical Care Medicine Exam: Format, Blueprint & Study Strategy

2 Chapter 2: Acute Respiratory Failure & ARDS

2.1 ARDS Definition, Pathophysiology & Phenotypes 2.2 Lung-Protective Mechanical Ventilation 2.3 Refractory ARDS: Prone Positioning, Neuromuscular Blockade & VV-ECMO

3 Chapter 3: Obstructive Airways, Pulmonary Vascular & Pleural Emergencies

3.1 Severe Asthma & COPD Exacerbations in the ICU 3.2 Massive & Submassive Pulmonary Embolism 3.3 Pulmonary Hypertension & Right Ventricular Failure in the ICU 3.4 Massive Hemoptysis, Complex Pleural Effusions & Thoracic Drainage

4 Chapter 4: Airway, Parenchymal & Nonthrombotic Pulmonary Emergencies

4.1 Airway Management, Upper-Airway Obstruction & Artificial-Airway Complications 4.2 Diffuse Alveolar Hemorrhage, Interstitial Lung Disease, Pulmonary Vasculitis & Noncardiogenic Edema 4.3 Severe Community-Acquired & Viral Pneumonia 4.4 Nonthrombotic Embolism (Air, Fat, Amniotic Fluid, Tumor, Septic) & Acute Chest Syndrome

5 Chapter 5: Mechanical Ventilation Modes, Dyssynchrony & Liberation

5.1 Mechanical Ventilator Modes & Advanced Breath Delivery 5.2 Patient-Ventilator Dyssynchrony & Waveform Analysis 5.3 Ventilator Liberation, Spontaneous Breathing Trials & Post-Extubation Support

6 Chapter 6: Shock Syndromes & Hemodynamic Principles

6.1 Shock Classification, Cellular Pathophysiology & Biomarkers 6.2 Hemodynamic Monitoring: Arterial Lines, CVP & Pulmonary Artery Catheter 6.3 Dynamic Assessment of Fluid Responsiveness & Resuscitation Targets

7 Chapter 7: Vasoactive Therapies & Mechanical Circulatory Support

7.1 Vasopressors & Inotropes: Pharmacology & Clinical Titration 7.2 Temporary Mechanical Circulatory Support: IABP, Impella & TandemHeart 7.3 Venoarterial ECMO (VA-ECMO) & Differential Hypoxemia 7.4 Post-Cardiac Arrest Care, Targeted Temperature Management & Neuroprognostication

8 Chapter 8: Acute Kidney Injury & Renal Replacement Therapy

8.1 KDIGO AKI Classification, Etiologies & Diagnostic Evaluation 8.2 Continuous Renal Replacement Therapy (CRRT) vs Intermittent Hemodialysis 8.3 Indications & Timing for RRT in Critical Illness: AKIKI & STARRT-AKI

9 Chapter 9: Electrolyte, Acid-Base & Endocrine Emergencies

9.1 Severe Dysnatremias: Hyponatremia, Hypernatremia & Osmotic Demyelination 9.2 Potassium, Calcium, Magnesium & Phosphate Disorders 9.3 Complex & Mixed Acid-Base Disorders: Boston vs Copenhagen vs Stewart 9.4 Endocrine Crises: DKA, HHS, Thyroid Storm, Myxedema Coma & Adrenal Crisis

10 Chapter 10: Glycemic Control, Hyperammonemia, Pituitary & Adrenal Disorders

10.1 ICU Glycemic Control & Severe Hypoglycemia 10.2 Non-Hepatic Hyperammonemia & Metabolic Encephalopathy 10.3 Pituitary Emergencies, Adrenal Excess & Critical Illness-Related Corticosteroid Insufficiency

11 Chapter 11: Acute Coronary Syndromes & Cardiac Arrhythmias

11.1 Acute Coronary Syndromes & Mechanical Complications of Myocardial Infarction 11.2 Critical Tachyarrhythmias: Atrial Fibrillation with RVR, VT & VF 11.3 Critical Bradyarrhythmias, Conduction Blocks & Temporary Cardiac Pacing

12 Chapter 12: Acute Heart Failure, Valvular & Pericardial Emergencies

12.1 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 12.2 Acute Valvular Regurgitation & Prosthetic Valve Emergencies 12.3 Pericardial Tamponade & Acute Aortic Syndromes

13 Chapter 13: Myocardial Disease, Hypertensive & Cardiac Device Emergencies

13.1 Fulminant Myocarditis, Stress & Peripartum Cardiomyopathy, and Hypertrophic Cardiomyopathy 13.2 Hypertensive Emergencies & Ruptured Abdominal Aortic Aneurysm 13.3 Implanted Cardiac Devices, LVAD Emergencies & Electrical Storm

14 Chapter 14: Sepsis & Systemic Infectious Diseases

14.1 Sepsis-3 Definitions & Surviving Sepsis Campaign 2026 Guidelines 14.2 Refractory Septic Shock & Adjunctive Therapies 14.3 Multidrug-Resistant Pathogens & Antimicrobial Stewardship in the ICU

15 Chapter 15: ICU-Acquired & Severe Focal Infections

15.1 Hospital-Acquired & Ventilator-Associated Pneumonia 15.2 Central Line-Associated Bloodstream Infections & Catheter-Associated UTIs 15.3 Intra-Abdominal Sepsis, Necrotizing Soft Tissue Infections & CNS Infections

16 Chapter 16: Focal, Special-Host & Systemic Infections

16.1 CNS Infections Beyond Bacterial Meningitis: Encephalitis, Brain Abscess & Epidural Abscess 16.2 Infections in the Immunocompromised Host, Tropical & Bioterror Infections 16.3 Infective Endocarditis, Device Infections & Other Focal Cardiovascular Infections 16.4 Antimicrobial Pharmacokinetics, Allergy, Toxicity & Infection Prevention 16.5 Gastrointestinal & Hepatobiliary Infections: Fulminant C. difficile, Typhlitis, CMV Colitis & Abscesses

17 Chapter 17: Neurocritical Care & Coma

17.1 Coma, Altered Mental Status & Acute Delirium in the ICU 17.2 Status Epilepticus & Non-Convulsive Status Epilepticus 17.3 Acute Ischemic Stroke & Intracranial Hemorrhage

18 Chapter 18: Cerebrovascular Syndromes, Encephalopathy & Withdrawal States

18.1 Cerebral Venous Sinus Thrombosis, PRES & Reversible Cerebral Vasoconstriction Syndrome 18.2 Alcohol & Sedative Withdrawal, Wernicke Encephalopathy & Drug-Induced Encephalopathy

19 Chapter 19: Intracranial Hypertension & Neuromuscular Weakness

19.1 Intracranial Pressure Monitoring, Cerebral Perfusion & Tiered ICP Management 19.2 Acute Neuromuscular Respiratory Failure, ICU-Acquired Weakness & Brain Death Determination

20 Chapter 20: Traumatic Brain Injury, Spinal Cord Injury & Toxin-Mediated Paralysis

20.1 Traumatic Brain Injury Management & Paroxysmal Sympathetic Hyperactivity 20.2 Acute Spinal Cord Injury, Neurogenic Shock & Autonomic Dysreflexia 20.3 Toxin-Mediated Paralysis & Neuromuscular Crises: Botulism, Tetanus, Tick Paralysis & Myasthenic Crisis

21 Chapter 21: Gastrointestinal, Hepatic & Abdominal Emergencies

21.1 Acute Upper & Lower Gastrointestinal Bleeding in the ICU 21.2 Acute Liver Failure & Severe Acute Pancreatitis 21.3 Abdominal Compartment Syndrome & Acute Mesenteric Ischemia

22 Chapter 22: Luminal GI Emergencies & Complications of Cirrhosis

22.1 Esophageal, Gastric & Bowel Emergencies: Perforation, Obstruction, Ogilvie Syndrome & Colonic Ischemia 22.2 Complications of Cirrhosis: Alcohol-Associated Hepatitis, Hepatorenal Syndrome & Pulmonary Vascular Syndromes

23 Chapter 23: Trauma, Burns & Perioperative Critical Care

23.1 Polytrauma Resuscitation, Damage Control & Massive Transfusion 23.2 Severe Burn Injury, Inhalation Injury & Environmental Emergencies 23.3 Perioperative Critical Care for High-Risk Surgical Patients

24 Chapter 24: Thoracic Trauma, Environmental Injury & Obstetric Critical Care

24.1 Thoracic Trauma: Flail Chest, Pulmonary Contusion, Great Vessel & Tracheobronchial Injury 24.2 Environmental Injury: Drowning, Diving, Altitude, Heat, Cold, Electrical & Radiation 24.3 Obstetric & Genitourinary Emergencies and the Physiology of Pregnancy

25 Chapter 25: Transplantation, Donor Management & Post-Cardiac Surgery Care

25.1 Solid Organ Transplant Recipients & Deceased Donor Management 25.2 Post-Cardiac Surgery Critical Care: Bleeding, Tamponade, Low Output & Vasoplegia

26 Chapter 26: Hematologic Emergencies, Toxicology, Critical Ultrasound & ICU Liberation

26.1 Hematologic Emergencies in the ICU: HIT, DIC, TMA & Anticoagulant Reversal 26.2 Critical Care Toxicology, Toxidromes & Specific Antidotes 26.3 Critical Care Point-of-Care Ultrasound (POCUS) 26.4 ICU Liberation, Analgosedation, Goals of Care & Critical Care Ethics

27 Chapter 27: Transfusion Medicine, Hematologic & Oncologic Disorders

27.1 Transfusion Medicine: Products, Thresholds, Reactions & Apheresis 27.2 Red and White Cell Disorders, Hemoglobinopathies, Factor Deficiencies & Hypercoagulable States 27.3 Oncologic Emergencies, Hematopoietic Cell Transplant Complications & Cellular Therapy Toxicity

28 Chapter 28: Clinical Pharmacology, Adverse Drug Reactions & Specific Poisonings

28.1 Pharmacokinetic Principles, Dose Adjustment & Drug Interactions in Critical Illness 28.2 Adverse Drug Reactions: Anaphylaxis, Severe Cutaneous Reactions & Hyperthermic Syndromes 28.3 Specific Poisonings: Sodium-Channel Blockers, Lithium, Valproate, Theophylline, Iron, Sulfonylureas & Methemoglobinemia

29 Chapter 29: Ethics, Research Methods, Administration & Abdominal Ultrasound

29.1 Advance Care Planning, Nonbeneficial Treatment, Informed Consent & Confidentiality 29.2 Critical Care Research Methods, Statistics, IRB Oversight & Quality Improvement 29.3 Abdominal, Vascular & Procedural Point-of-Care Ultrasound

3.4 Massive Hemoptysis, Complex Pleural Effusions & Thoracic Drainage

Key Takeaways Explain This Topic AI

Massive hemoptysis is clinically defined by bleeding volume that results in airway compromise, asphyxiation, or gas exchange failure (traditionally >100-600 mL/24 hr); the primary threat to life is asphyxiation, not blood loss.

Approximately 90% of massive hemoptysis originates from the high-pressure systemic bronchial arterial circulation, making urgent bronchial artery embolization (BAE) the definitive interventional treatment of choice.

Airway protection requires positioning the bleeding lung dependent (lateral decubitus), intubation with a large-bore single-lumen endotracheal tube (≥8.0 mm) to facilitate bronchoscopy, or selective mainstem intubation/bronchial blocker isolation.

Complicated parapneumonic effusions and empyema are diagnosed by pleural fluid analysis (pH <7.20, glucose <60 mg/dL, LDH >1000 IU/L, or positive Gram stain/culture) and mandate prompt tube thoracostomy drainage.

The MIST-2 trial protocol established that combined intrapleural tPA (10 mg) and human recombinant DNase (5 mg) twice daily for 3 days improved radiographic pleural drainage (primary outcome) and, as secondary outcomes, reduced surgical referral and hospital length of stay in pleural infection.

Last updated: October 2026

Thoracic emergencies involving the conducting airways, pulmonary vasculature, and pleural space are frequent sources of acute respiratory decompensation in the ICU. Life-threatening hemoptysis, loculated parapneumonic effusions, empyema, and tension pneumothorax require swift clinical recognition, mastery of invasive diagnostic testing, and immediate procedural interventions.

• Massive Hemoptysis: Pathophysiology & Vascular Origins
• Definition and Clinical Significance

Massive (life-threatening) hemoptysis is defined clinically as any rate of hemoptysis that impairs gas exchange, causes upper airway obstruction, or produces hemodynamic instability , regardless of measured volume. Quantitatively, it is traditionally defined as bleeding exceeding 100 to 600 mL within a 24-hour period (or > 150 mL/hour >150\text{ mL/hour} > 150 mL/hour ).

Warning

Patients with massive hemoptysis die from asphyxiation and drowning , not exsanguination! The anatomic dead space of the human conducting airway is only approximately 150 mL 150\text{ mL} 150 mL . Rapid extravasation of even modest volumes of blood can overwhelm alveolar gas exchange, cast the bronchial tree with obstructive blood clots, and trigger fatal hypoxemic cardiac arrest.

Dual Vascular Supply of the Lung

Vascular System Hemodynamic Characteristics Contribution to Massive Hemoptysis Common Etiologies

Bronchial Arteries Arise from thoracic aorta or intercostal vessels; high-pressure systemic circulation ( 120 / 80 mmHg 120/80\text{ mmHg} 120/80 mmHg ) ~90% of all massive hemoptysis cases Bronchiectasis, cavitary tuberculosis, lung carcinoma, chronic necrotizing pneumonia, aspergilloma, cystic fibrosis

Pulmonary Arteries Arises from right ventricle; low-pressure circulation ( 25 / 10 mmHg 25/10\text{ mmHg} 25/10 mmHg ) ~10% of cases Pulmonary infarction (PE), vascular malformations (AVMs), Rasmussen aneurysm (cavitary TB erosion), iatrogenic pulmonary artery catheter rupture

In chronic inflammatory lung diseases, angiogenesis driven by vascular endothelial growth factor (VEGF) induces extensive proliferation of tortuous, thin-walled, fragile bronchial arteries. These systemic-pressure vessels readily rupture under high shear stress or active infection.

Immediate Emergency Management of Massive Hemoptysis Immediate Management Algorithm for Massive Hemoptysis:

• MASSIVE HEMOPTYSIS ENCOUNTERED
• │
• ▼
• STEP 1: POSITIONING
• Place patient in LATERAL DECUBITUS position with BLEEDING LUNG DEPENDENT
• Prevents blood from spilling into and drowning the healthy contralateral lung
• │
• ▼
• STEP 2: AIRWAY PROTECTION & RESUSCITATION
• High-flow oxygen / prepare for immediate intubation
• Intubate with LARGE-BORE single-lumen ETT (≥8.0–8.5 mm)
• Large caliber allows passage of therapeutic flexible bronchoscope (5.9–6.3 mm)
• Preload with crystalloid, initiate massive transfusion protocol if coagulopathic
• │
• ▼
• STEP 3: LOCALIZATION & ENDOBRONCHIAL TAMPONADE

• Urgent flexible bronchoscopy in ICU:

• Iced saline lavage (50 mL aliquots at 4°C)
• Topical tranexamic acid (500–1,000 mg endobronchial)
• Topical epinephrine (1:20,000 or 1:100,000 dilution)
• Advance endobronchial blocker (Fogarty catheter) into bleeding bronchus
• Alternatively: Selective mainstem intubation of the healthy lung
• │
• ▼
• STEP 4: DEFINITIVE ANGIOGRAPHIC EMBOLIZATION
• Emergent Catheter Angiography & Bronchial Artery Embolization (BAE)
• Embolize abnormal systemic vessels with microparticles
• CRITICAL: Identify and avoid the Artery of Adamkiewicz (spinal ischemia risk)
• Airway Management Nuances

Single-Lumen vs. Double-Lumen Tube (DLT): While a DLT allows complete anatomical lung separation, its placement in an actively hemorrhaging, coughing patient is technically challenging and frequently impossible. Furthermore, each lumen of a DLT is narrow ( 4 mm ~4\text{ mm} 4 mm ), preventing passage of a standard therapeutic flexible bronchoscope and becoming rapidly occluded by thick clots. Therefore, a large single-lumen tube ( ≥ 8.0 – 8.5 mm \ge 8.0–8.5\text{ mm} ≥ 8.0–8.5 mm ) is the standard of care in the ICU , combined with an endobronchial blocker or selective right/left mainstem intubation under direct bronchoscopic visualization.

Definitive Intervention: Bronchial Artery Embolization (BAE)

Emergent transcatheter bronchial artery embolization (BAE) performed by interventional radiology is the definitive first-line procedure for massive hemoptysis, achieving acute hemostasis in > 85 – 90 % >85–90\% > 85–90% of cases.

Angiography identifies hypertrophied, tortuous bronchial arteries, systemic-to-pulmonary shunts, and contrast extravasation. Embolization is accomplished using polyvinyl alcohol (PVA) particles ( 300 – 500 μ m 300–500\ \mu\text{m} 300–500 μ m ) or microspheres.

Caution

The most feared complication of BAE is anterior spinal cord ischemia (anterior spinal artery syndrome) resulting in acute paraplegia. The operator must meticulously identify the spinal arteries—specifically the artery of Adamkiewicz (arteria radicularis magna), which arises from an intercostobronchial trunk in up to 5% of patients—prior to releasing embolic particles.

• Complex Pleural Effusions & Empyema
• Diagnostic Thoracentesis & Light's Criteria

Diagnostic thoracentesis should be performed promptly for any unexplained pleural collection > 10 mm >10\text{ mm} > 10 mm thickness on decubitus radiography or thoracic ultrasonography. Fluid is analyzed to differentiate an exudate from a transudate using Light's criteria : Light's Criteria for Exudative Pleural Effusion:

(Effusion is an EXUDATE if at least ONE of the following is present):

• ├── 1. Pleural fluid protein / Serum protein ratio > 0.5
• ├── 2. Pleural fluid LDH / Serum LDH ratio > 0.6
• └── 3. Pleural fluid LDH > 2/3 the upper limit of normal laboratory serum LDH
• Staging Parapneumonic Effusions

Parapneumonic effusions progress through three continuous stages: exudative (simple), fibropurulent (complicated), and organizational (empyema).

Classification Gross Appearance Biochemical Criteria Microbiologic Analysis Drainage Requirement

Simple (Uncomplicated) Serous, clear fluid pH > 7.30 \text{pH} > 7.30 pH > 7.30 , Glucose > 60 mg/dL \text{Glucose} > 60\text{ mg/dL} Glucose > 60 mg/dL , LDH < 1000 IU/L \text{LDH} < 1000\text{ IU/L} LDH < 1000 IU/L Negative Gram stain and culture Antibiotics alone; no chest tube required

Complicated Parapneumonic Cloudy, turbid fluid pH < 7.20 \text{pH} < 7.20 pH < 7.20 , Glucose < 60 mg/dL \text{Glucose} < 60\text{ mg/dL} Glucose < 60 mg/dL , LDH > 1000 IU/L \text{LDH} > 1000\text{ IU/L} LDH > 1000 IU/L May be positive or negative (bacteria cleared from space) Mandatory tube thoracostomy drainage

Empyema Frank pus, viscous Marked acidosis ( pH < 7.10 \text{pH} < 7.10 pH < 7.10 ), unmeasurable glucose Positive Gram stain or bacterial culture Mandatory tube thoracostomy drainage

Important

A pleural fluid pH < 7.20 \text{pH} < 7.20 pH < 7.20 in a parapneumonic effusion indicates intense bacterial metabolic consumption and accumulation of lactic acid. Antibiotics cannot penetrate or sterilize an acidic, complicated effusion; failure to immediately place a chest tube leads to dense fibrothorax, loculation, and sepsis .

The MIST-2 Trial Protocol for Loculated Empyema

When complicated effusions or empyemas develop dense fibrin septations and loculations, standard chest tube drainage often fails because the fluid cannot navigate the loculated pockets.

The landmark MIST-2 Trial ( Second Multicentre Intrapleural Sepsis Trial , NEJM 2011) evaluated 210 patients with pleural infection randomized to four arms: intrapleural tPA plus DNase, tPA alone, DNase alone, or double placebo:

The Regimen:

Tissue Plasminogen Activator (Alteplase / tPA): 10 mg instilled intrapleurally.

Human Recombinant Deoxyribonuclease (DNase / Pulmozyme): 5 mg instilled intrapleurally.

Both agents administered concurrently twice daily for 3 days (total of 6 doses) .

Following instillation, the chest tube is clamped for 1 to 2 hours to allow enzyme activity before unclamping to continuous negative suction ( − 20 cmH 2 O -20\text{ cmH}_2\text{O} − 20 cmH 2 ​ O ).

Mechanistic Synergy: tPA breaks down the thick fibrin meshwork of loculations, while DNase hydrolyzes free extracellular DNA released by lysed neutrophils, dramatically lowering fluid viscosity.

Outcomes: The combined tPA/DNase protocol produced a marked, statistically significant reduction in radiographic pleural opacity ( p < 0.001 p < 0.001 p < 0.001 ), reduced the need for surgical rescue (video-assisted thoracoscopic surgery [VATS] or open thoracotomy) by 75% (odds ratio 0.17, p = 0.03 p = 0.03 p = 0.03 ; a secondary outcome), and shortened hospital stay by an average of 6.7 days. Monotherapy with tPA alone or DNase alone showed no clinical benefit over placebo.

• Tension Pneumothorax & Thoracic Drainage Principles
• Pathophysiology of Tension Pneumothorax

Tension pneumothorax develops when a one-way tissue valve allows atmospheric or positive-pressure gas to enter the pleural space during inspiration without escape during expiration. Progressive intrapleural air accumulation causes intrapleural pressure to exceed ambient atmospheric and central venous pressures, with rapid catastrophic results: One-Way Pleural Valve Air Leak

• │
• ▼
• Massive Positive Intrapleural Pressure
• │
• ▼
• Total Collapse of Ipsilateral Lung
• │
• ▼
• Mediastinal Shift to the Contralateral Hemithorax
• │
• ▼
• Torsion and Compression of Superior & Inferior Vena Cava
• │
• ▼
• Acute Reduction in Right Atrial Venous Return
• │
• ▼
• Obstructive Shock & Imminent Cardiac Arrest
• Clinical Presentation & Emergency Management

Diagnosis is Entirely Clinical: Marked tachypnea, severe respiratory distress, acute cyanosis, hypotension, tachycardia, ipsilateral absent breath sounds, hyperresonance to percussion, distended neck veins, and contralateral tracheal deviation. Never delay intervention to obtain a confirmatory chest radiograph in an unstable patient!

Emergent Needle Decompression:

Insert a large-bore (14-gauge or 16-gauge, ≥ 5 – 8 cm \ge 5–8\text{ cm} ≥ 5–8 cm length) needle catheter:

Second intercostal space at the midclavicular line , immediately superior to the third rib (to avoid the intercostal neurovascular bundle running along the inferior rib groove).

Alternatively: Fourth or fifth intercostal space at the anterior axillary line (frequently preferred in muscular or obese patients due to thinner chest wall anatomy).

Tube Thoracostomy: Needle decompression must be followed immediately by formal tube thoracostomy (chest tube, typically 24 – 28 French 24–28\text{ French} 24–28 French for hemothorax/trauma, or 14 – 20 French 14–20\text{ French} 14–20 French for simple pneumothorax) connected to a three-chamber water seal suction apparatus.

• Mechanics of the Three-Chamber Drainage System Three-Chamber Pleural Drainage System
• │
• ┌────────────────────────────────┼────────────────────────────────┐
• ▼ ▼ ▼
• 1. Collection Chamber 2. Water Seal Chamber 3. Suction Control Chamber
• Receives fluid/blood • Acts as a one-way valve • Governs applied suction
• Calibrated volume measurement • Allows air to escape; prevents (typically -20 cmH2O)
• Monitored for hourly output ambient air from re-entering • Bubbling confirms suction
• Continuous bubbling indicates level is actively driven
• persistent air leak (fistula)

Evaluating Air Leaks: Continuous bubbling in the water seal chamber during both inspiration and expiration indicates an active, persistent bronchopleural fistula or an external leak in the tubing circuit. Bubbling that occurs only during expiration or coughing indicates a resolving air leak as the lung re-expands.